Coronavirus
Moderna Inks Deal With Kenya To Establish A $500M Vaccine Making Plant In The Country

Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that with the assistance of the U.S. Government, it has entered into a Memorandum of Understanding with the Government of the Republic of Kenya to establish Kenya as the location for the Company’s mRNA manufacturing facility.
Moderna is building this state-of-the-art mRNA facility in Africa with the goal of producing up to 500 million doses of vaccines each year. The Company anticipates investing up to $500 million in this new facility which will focus on drug substance manufacturing on the continent of Africa for the continent of Africa, and could also be expanded to include fill/finish and packaging capabilities at the site. In parallel, Moderna is also working on plans to allow it to fill doses of its COVID-19 vaccine in Africa as early as 2023, subject to demand.
We were honored to participate in a signing ceremony today with President of the Republic of Kenya, Uhuru Kenyatta; Cabinet Secretary Mutahi Kagwe; Dr. John Nkengasong, Director of the Africa CDC and Eric Kneedler, Chargé d’Affaires ad interim at the U.S. Embassy in Nairobi. pic.twitter.com/BxT2xOPHFK
— Moderna (@moderna_tx) March 7, 2022
“Battling the COVID-19 pandemic over the last two years has provided a reminder of the work that must be done to ensure global health equity. Moderna is committed to being a part of the solution and today, we announce another step in this journey – an investment in the Republic of Kenya to build a drug substance mRNA manufacturing facility capable of supplying up to 500 million doses for the African continent each year,” said Stéphane Bancel, Chief Executive Officer of Moderna. “With our mRNA global public health vaccine program, including our vaccine programs against HIV and Nipah, and with this partnership with the Republic of Kenya, the African Union and the U.S. Government, we believe that this step will become one of many on a journey to ensure sustainable access to transformative mRNA innovation on the African continent and positively impact public health.”
“Partnerships are key to our goal of deploying vaccines whenever and wherever they are needed,” said Noubar Afeyan, Moderna’s co-Founder and Chairman. “We would like to thank the Government of the Republic of Kenya for their support in bringing our mRNA manufacturing facility to Kenya, and thank the U.S. Government for assisting us in this process. We take seriously our critical role in combatting the COVID-19 pandemic and are determined to expand our global impact with our first manufacturing facility on the continent of Africa.”
“We are pleased to partner with Moderna in the establishment of this mRNA manufacturing facility to help prepare the country and our sister states on the continent through the African Union to respond to future health crises and stave off the next pandemic,” said His Excellency Uhuru Kenyatta, President of the Republic of Kenya. “This partnership is a testament to the capabilities of our community and our commitment to technological innovation. Moderna’s investment in Kenya will help advance equitable global vaccine access and is emblematic of the structural developments that will enable Africa to become an engine of sustainable global growth.”
“Kenya recognizes and appreciates the collaboration of Moderna in building our local manufacturing capacity. This will ensure as a country and region we can quickly respond to health demands requiring vaccine commodities,” said Sen. Mutahi Kagwe, Cabinet Secretary for Health of the Republic of Kenya.
“Ending COVID-19 is a top priority of the Biden Administration and this can be achieved with increased global cooperation and investment. The agreement announced today between Moderna and the Government of Kenya to build a vaccine production facility in Kenya will not only contribute to ending this pandemic, but to long-term advancements in research and development on the African continent to combat future ones,” said Jose W. Fernandez, U.S. Under Secretary for Economic Growth, Energy, and the Environment.
In its prophylactic vaccines modality, Moderna’s mRNA pipeline includes 28 vaccine programs including vaccines against respiratory viruses, vaccines against latent viruses and vaccines against threats to global public health.
Kenya Insights allows guest blogging, if you want to be published on Kenya’s most authoritative and accurate blog, have an expose, news TIPS, story angles, human interest stories, drop us an email on [email protected] or via Telegram
-
News6 days ago
Plane Carrying Raila Odinga Becomes World’s Most Tracked Flight as Kenya Airways Honors Him With Special Call Sign ‘RAO001’
-
News2 weeks ago
Former Nairobi CEC Newton Munene Found Dead as Sonko Alleges Cartel Involvement
-
Business1 day ago
Safaricom’s Sh115 Trillion Data Breach Scandal: How Kenya’s Telecom Giant Sold Out 11.5 Million Customers
-
News6 days ago
I Used To Sleep Hungry, But Today I Employ The Same People Who Once Laughed At My Poverty
-
Investigations6 days ago
Kwale Sugar Faces Liquidation Guillotine as Supreme Court Slams Door on Last-Ditch Rescue Bid
-
News5 days ago
Maurice Ogeta, Raila’s Bodyguard: The Shadow Who Became The Story
-
News1 week ago
Inside 17 Minutes: CCTV Footage Reveals Murdered State House Guard Was Well Known to The Killer
-
News2 weeks ago
Four Arrested In JKIA Cocaine Cartel Crackdown